Tue, May 13, 12:23 PM (36 days ago)
**Artelo Biosciences, Inc. (ARTL) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** No revenue generated. - **Profit Margins:** Negative, with a net loss of $2.4 million. - **Cash Flow:** Negative cash flow from operations at $1.6 million. - **Earnings Changes:** Net loss increased by $111,000 compared to Q1 2024. **Quarterly Performance Discussion:** - **Operating Expenses:** Decreased by $210,000 to $2.4 million. - **General & Administrative Expenses:** Decreased by $87,000 to $995,000. - **Research & Development Expenses:** Decreased by $123,000 to $1.4 million. - **Cash Flow from Operations:** Improved by $1.3 million to a negative $1.6 million. - **Cash Flow from Investing Activities:** No cash provided in Q1 2025. - **Cash Flow from Financing Activities:** No cash provided in Q1 2025. **Trends & Uncertainties:** - **Funding Requirements:** Significant capital needed for operations and development. - **Cash Position:** $0.7 million in cash and cash equivalents as of March 31, 2025. - **Future Operations Impact:** Dependent on additional funding through equity or debt offerings. **Key Risks:** - **Going Concern:** Substantial doubt about the ability to continue as a going concern. - **Regulatory & Market Risks:** Dependence on regulatory approvals and market acceptance. - **Operational Risks:** Dependence on third-party suppliers and manufacturers. - **Financial Risks:** Need for additional funding to sustain operations. **Future Outlook:** - **Funding:** Plans to raise additional capital through equity or debt offerings. - **Development:** Continued focus on product candidates and clinical trials. - **Market:** Uncertain market acceptance and competitive landscape.